ArticleBJUI compass2025
Long-term outcome of transurethral laser ablation for recurrent non-muscle invasive bladder cancer: An EORTC risk-matched study.
Article in BJUI compass, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Factors associated with flexible cystoscope longevity: an analysis of supplier and health service datasets.BJU international · 2026Article
- High feasibility and safety of office-based transurethral laser ablation for recurrent non-muscle invasive bladder cancer: a single-center experience.Frontiers in oncology · 2026Article
- Long-term outcome of transurethral laser ablation for recurrent non-muscle invasive bladder cancer: An EORTC risk-matched study.BJUI compass · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Elderly and comorbid patients with non-muscle invasive bladder cancer (NMIBC) often undergo repeated transurethral resection of bladder tumour (TURBT) under general anaesthesia. Transurethral laser ablation (TULA) is an outpatient-based alternative with lower morbidity, cost and carbon footprint, but its long-term efficacy is not well-established. We report the long-term outcomes of recurrent NMIBC treated with TULA, stratified by European Organisation for Research and Treatment of Cancer (EORTC) risk groups. Materials and Methods: We conducted a single-centre, retrospective cohort study, including all consecutive NMIBC patients treated with TULA between 2012 and 2023. The primary outcomes were recurrence-free survival (RFS) and progression-free survival (PFS) and secondary outcomes included cancer-specific survival (CSS), overall survival (OS) and complications, stratified by EORTC risk groups. Data were analysed using Kaplan-Meier survival analysis and Cox regression model. Results: Three hundred and nineteen patients (1186 TULAs), with a median age of 77 and median Charleson Comorbidity Index of 7, were included. Median follow up was 4.4 years. The 5-year RFS of intermediate-risk and high-risk NMIBC treated with TULA were 31.8% (95%CI:25.6-39.7%) and 29.0% (95%CI: 20.1-42.0%), respectively, with no significant difference (p:0.47). The 5-year PFS were 86.8% (95%CI: 82.1-91.7%) and 93.1% (95%CI: 85.2-100.0%), respectively. Overall, the 10-year OS and CSS were 50.7% (95% CI: 41.8-61.5%) and 96.1% (95%CI: 93.3-98.9%), respectively. The complication rate was 4.0%. Age was the only positive predictor of recurrence. Limitations include missing data (7.9%) and single-centre retrospective design. Conclusion: TULA is a safe, minimally invasive treatment with long-term efficacy for elderly and comorbid patients with recurrent NMIBC. Although recurrence rate at 5 years were high, progression rate, especially muscle invasion, was low and reassuring. Long-term overall survival and cancer-specific survival remained excellent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.